Mark DiPaolo
On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.
Highest-materiality recent filing
Innoviva directors Small and DiPaolo resign; Josephine Linden elected to board
Derek Small (CEO of Syndeio) and Mark DiPaolo resigned May 12 to focus on Syndeio growth.
Innoviva Q1 revenue $98M (+11% YoY); IST sales surge 37%; net income $186.6M
Total revenue $98.0M, up 11% YoY; GSK royalty revenue $58.6M (down from $61.3M).
Innoviva shareholders reelect board, approve compensation and equity plan
All five director nominees elected: Small (56.8M for), DiPaolo (50.1M), Haimovitz (56.8M), Schlesinger (53.5M), Raifeld (58.9M).
Innoviva Q4 revenue up 25% to $114.6M; net income $164.2M; NUZOLVENCE approved
Full year 2025 revenue $411.3M (+15% YoY); net income $271.2M ($4.02 basic EPS).
Innoviva Q3: Revenue $107.8M (+20% YoY), Net Income $89.9M, $125M Buyback
Total revenue $107.8M (+20% YoY); GSK royalty $63.4M; net product sales $47.3M (U.S. $29.9M, +52% YoY).
Innoviva Q2 2025 net income $63.7M; product sales up 54% YoY; zoliflodacin PDUFA Dec 15
Q2 2025 net income $63.7M ($1.01 basic EPS) vs net loss of $34.7M in Q2 2024.
Innoviva stockholders elect five directors and approve advisory compensation vote
All five director nominees elected: Derek Small, Mark DiPaolo, Jules Haimovitz, Sarah Schlesinger, Pavel Raifeld.
On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.
On May 18, 2026, following the resignations of Messrs. Small and DiPaolo, the Board elected Josephine Linden to serve as a member of the Board of Directors (the “Linden Effective Date”).
On May 12, 2026, Derek Small and Mark DiPaolo Esq. tendered their resignations from the Board of Directors of Innoviva, Inc.
Max materiality 0.75 · Median 0.75 · Most common event earnings